Growth in the pipeline of dry eye disease therapeutics is anticipated over next few years on account of increasing incidences of people being diagnosed with diabetes and deficiency of vitamins such as A and B, which is majorly caused due to change in dietary intake and unhealthy lifestyle. This in turn leads to increase in risk of ocular infections and other bothersome symptoms such as visual disturbance, ocular discomfort and fatigue, in people. To overcome these problems, increasing number of companies are engaged in the process of developing drugs and devices that would assist in curing the disease. On the back of this, growth in the therapeutics pipeline of dry eye disease is anticipated. Additionally, increase in healthcare awareness and knowledge related to the various problem caused by environmental factors such as pollution, are also contributing to the growth of the pipeline.
Dry eye disease usually occurs when eyes do not produce tears or the same is done in inconsistent proportion, due to which eyes lack moisture. The dry eye disease is also associated with inflammation in eye which can cause pain, scar on cornea, ulcer and sometimes, permanent loss of vision, due to which a person is unable to read properly and perform the daily tasks. The dry eye disease is also known as, keratoconjunctivitis sicca, dysfunctional tear disease, lacrimal keratoconjunctivitis, evaporative tear deficiency, LASIK-induced neurotrophic epitheliopathy and aqueous tear deficiency. The dry eye disease can be broadly classified into – aqueous tear-deficient dry eye and evaporative dry eye. The aqueous tear-deficient dry eye is a condition in which the lacrimal glands are unable to produce tears; whereas, evaporative dry eye problem occurs due to inflammation of meibomian glands.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/dry-eye-disease-therapeutics-pipeline-analysis/toc-sample
In September 2011, Bristol-Myers Squibb Company, and Ono Pharmaceutical Co., Ltd. entered into an agreement to expand Bristol-Myers Squibb’s territorial rights to develop and commercialize the anti-PD-1 antibody known as BMS-936558/ONO-4538, and to create a strategic alliance for the co-development and co-commercialization of ORENCIA (abatacept) in Japan. Also, under the agreement the companies were to co-develop and co-commercialize ORENCIA, a biologic therapy for rheumatoid arthritis, in Japan. The agreement applied to both the approved intravenous formulation of ORENCIA and the subcutaneous formulation of ORENCIA, including all current and future indications.
Some of the companies having a pipeline of dry eye disease therapeutics include, Parion Sciences, Inc., Allergan Plc, Genentech, Inc., Kissei Pharmaceutical Co., Ltd., ReGenTree, LLC, Cell Cure Neurosciences Ltd., Regenerative Patch Technologies, LLC, Topivert Pharma Ltd.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)